Clean air for Pharmaxis

By Dylan Bushell-Embling
Wednesday, 13 August, 2008

Results from the Phase II clinical trial of Pharmaxis' [ASX: PXS] Bronchitol treatment in cystic fibrosis patients have produced promising results.

The study showed that Bronchitol was able to improve lung function in cystic fibrosis sufferers, as measured by forced vital capacity and FEV1 - the amount of air that can be forcibly exhaled in one second.

Improvements in lung function were dose-dependant, with the best results occurring in the patients which had received the highest dose. Pharmaxis has concluded that 400mg is the optimal Bronchitol dose.

Bronchitol is designed to hydrate the airway surface, improve lung hygiene and promote normal lung clearance. It is a proprietary formulation of mannitol, administered as a dry powder through a hand-held inhaler.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd